net debt total capit
medic suppli devic
sale
reason report
fundament intact intern transit impact quarter
bottom line bit complic
recent quarter could pressur share today
share weak today recommend buy given
underli fundament strong ad new
patient quarter ever compani histori
intern issu transient believ dramat
improv come quarter view diabet
devic overal appear adopt inflect
differenti footprint think well-posit
benefit disproportion possibl acceler
insulin pump market growth sale
came expect miss entir driven
intern repurchas distributor inventori europ
 omnipod sale actual exceed expect
come next-gen dash person diabet manag
limit launch late quarter us noth
quarter signal chang fundament continu
believ well posit achiev sale target
driven broader market access coverag expans
patient fall medicar medicaid
well unitedhealthcar op coverag continu pipelin
progress dash limit launch share gain
 anima exit pump market earli anecdot
patient upgrad pump omnipod rebuild
intern adopt momentum transit direct
reiter op pt pt appli ev/sal
multipl now-high sale estim share
current trade lower sale estim
expect multipl hold current level given believ
sustain double-digit growth next year path
profit key issu smid-cap med-tech investor believ
share deserv trade premium ev/sal
multipl smid-cap med-tech coverag univers
intern sale come midpoint guidanc
rang due excess inventori channel manag
expect increment impact lower
estim reflect transitori issu reduc sale
estim y/i previous
estim move y/i
compani inform leerink partner llc research
revenu ep figur includ fa option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rate share outperform price target next
year continu focu drive strong referr momentum increas sale
forc product greater awar deliv believ around
top-lin compound-annual-growth-rate time-frame ex neighborhood diabet underw
manag transit almost two year ago busi stabilized-to-
acceler believ long-term market opportun type patient unchang
new manag expand market opportun type patient broader
drug deliveri solid execut continu reinvest sale forc appear
pois drive sustain re-acceler new patient add beyond diabet
compani meaning opportun platform drug deliveri technolog non-insulin
sale underway expect ramp least total sale next
year base estim
continu rate share op price target appli
ev/revenu multipl now-low sale estim share current
trade sale estim expect multipl hold current
level given believ sustain double-digit growth next year
path profit key issu smid-cap med-tech investor believ
share deserv trade least high end ev/sal multipl smid-cap
risk includ failur success execut adopt omnipod type patient
potenti manufactur issu and/or inabl seamlessli ramp product failur
advanc pipelin artifici pancrea product failur bring success drug
deliveri partnership commerci increas competit higher us dollar
dollar million except per share data
total good sold
research develop expens
revenu
consensu incom statement item includ contributor factset
consensu detail revenu item first order analyt
consensu
compani report factset consensu first order analyt leerink partner estim
dollar million except per share data
total good sold
research develop expens
revenu
consensu incom statement item includ contributor factset
consensu detail revenu item first order analyt
consensu
compani report factset consensu first order analyt leerink partner estim
dollar million except per share data
total good sold
research develop expens
loss discontinu oper
sg sale
 sale
oper expens sale
compani report leerink partner estim
increas
dexcom cgm
autom insulin deliveri
essenti enabl omnipod
cgm speak one
clinic trial on-go
august stare studi enrol
patient expect complet octob
august expect complet trial
move final pre-pivot
start
enrol complet
believ possibl present data
ada
may expect data avail
run clinic trial
full control
actual
market two decad
good deliveri
system avail eli lilli
launch kwikpen late
pump avail market u-
effect increas
capac reservoir
enabl omnipod better serv
peopl higher insulin
requir peopl live
insulin depend type
diabet omnipod
omnipod doubl
